Skip to content
Open in App
Aeon Biopharma logo

Aeon Biopharma

web2

AEON Biopharma is an American clinical stage biotechnology company developing ABP450, a botulin...

Symbol ยท AEON
Company profile

About

AEON Biopharma is an American clinical stage biotechnology company developing ABP450, a botulinum toxin product intended for therapeutic use through a proposed biosimilar development pathway. The company is investigating whether its formulation can meet regulatory requirements for comparison with Botox, an established treatment used across several medical indications. Its development strategy focuses on therapeutic applications rather than cosmetic procedures, with the objective of expanding treatment options for patients and healthcare providers. AEON works with regulatory authorities on the clinical and scientific evidence required for its proposed biosimilar. ABP450 remains a development product rather than an approved therapeutic biosimilar.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNYSEPrimary symbol: AEON
Expert coverage

Aeon Biopharma profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment